Beam Therapeutics Inc. has announced that the U.S. Food and Drug Administration (FDA) has granted Regenerative Medicine Advanced Therapy (RMAT) designation to its investigational genetically modified cell therapy, BEAM-101, for the treatment of sickle cell disease. This designation, following the earlier orphan drug designation in June, underscores the potential of BEAM-101 as a transformative therapy for severe sickle cell disease. The RMAT designation will facilitate enhanced collaboration with the FDA as Beam Therapeutics progresses toward a Biologics License Application $(BLA.AU)$ filing. With updated data from the BEACON Phase 1/2 trial expected by the end of the year, Beam Therapeutics continues to focus on delivering this promising treatment to patients.